Vertex Pharmaceuticals (VRTX) Gets a Buy from Barclays
Barclays analyst Eliana Merle maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $607.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Merle is a 4-star analyst with an average return of 4.9% and a 43.33% success rate. Merle covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Alnylam Pharma, and BridgeBio Pharma.
In addition to Barclays, Vertex Pharmaceuticals also received a Buy from TipRanks – Google’s Google Biotechnology in a report issued on February 14. However, on the same day, TipRanks – Anthropic downgraded Vertex Pharmaceuticals (NASDAQ: VRTX) to a Hold.
Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.08 billion and a net profit of $1.08 billion. In comparison, last year the company earned a revenue of $2.77 billion and had a net profit of $1.05 billion
Read More on VRTX:
Disclaimer & DisclosureReport an Issue
- Vertex Pharmaceuticals Signals Confident Growth Beyond CF
- Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley
- Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank
- Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital
- Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein
